Clinical Application Analysis of the Combination of Ixekizumab and Methotrexate in the Treatment of Moderate to Severe Refractory Plaque Psoriasis and Sleep Quality
Clinical Application Analysis of the Combination of Ixekizumab and Methotrexate in the Treatment of Moderate to Severe Refractory Plaque Psoriasis and Sleep Quality
Objective:To explore the clinical application,safety,sleep quality,and adverse reactions of the combination of Ignitu-zumab and Methotrexate in the treatment of moderate to severe refractory plaque psoriasis.Methods:Sixty patients with moderate to severe refractory plaque psoriasis who visited the dermatology department of Fuqing Hospital and Xiamen Changgeng Hospital from April 2019 to January 2023 were selected as the study subjects.The control group received methotrexate once a week,taken orally for 12 weeks;on the basis of the control group,the observation group received treatment with IXE monoclonal antibody,subcutaneous injection of 300 mg,treatment for 1 week/time,continuous 5 times,and then once a month for a course of 12 weeks.Assess the severity and efficacy of psoriasis in patients using the Psoriasis Area Severity Index(PASI),Body Surface Area(BSA),and Pruritus numerical rating scale(PNRS);the Dermatology Life Quality Index(DLQI),Hamilton Depression Scale(HAMD)are used to evaluate the impact of moderate to severe refractory psoriasis on daily life,and the Pittsburgh Sleep Quality Index(PSQI)are used to assesses patients'sleep quality.Results:There was no dropout in the observation group,while there were 3 dropouts in the control group.Due to the lack of significant therapeutic effect for a long time,1 patient gave up treatment,and 2 patients were emotionally anxious and switched to biological therapy,all treated as dropouts.The PASI 50,PASI 75,and PA-SI 90 of the observation group were significantly higher than those of the control group after treatment(P＜0.001);after treat-ment,the patient's PASI,BSA,DLQI,and HAMD scores all showed significant improvement;IXE has high safety and low inci-dence of adverse reactions,after treatment,the PSQI score of patients was significantly improved,and the sleep quality of patients in the observation group was higher than that in the control group(P＜0.001).Conclusion:IXE has a clear therapeutic effect in the treatment of moderate to severe refractory plaque psoriasis.It can effectively improve the skin lesion area of patients with psori-asis,inhibit skin itching,improve their quality of life,alleviate depressive emotions,improve patients'sleep quality,have good safety,and a low incidence of adverse reactions.It can provide a reference basis for clinical treatment of moderate to severe refrac-tory plaque psoriasis.
关键词
依奇珠单抗/甲氨蝶呤/中重度难治性斑块型银屑病/临床应用/睡眠质量
Key words
Methotrexate/Moderate to Severe Refractory Plaque Psoriasis/Clinical Application/Sleep Quality
维普
万方数据